Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(31 sites)

United States

University of Alabama/Children's of Alabama, Birmingham, Alabama

Arkansas Children's Hospital, Little Rock, Arkansas

UCSF Benioff Children's Hospital Oakland, Oakland, California

Rady Children's Hospital, San Diego, California

Connecticut Children's Hospital, Hartford, Connecticut

Arnold Palmer Hospital for Children, Orlando, Florida

St. Joseph's Children's Hospital, Tampa, Florida

Augusta University Health, Augusta, Georgia

University of Iowa, Iowa City, Iowa

Norton Children's Research Institute/Affiliated with University of Louisville School of Medicine, Louisville, Kentucky

Helen DeVos Children's Hospital, Grand Rapids, Michigan

Children's Hospital and Clinics of Minnesota, Minneapolis, Minnesota

Children's Mercy Hospitals and Clinics, Kansas City, Missouri

Cardinal Glennon Children's Hospital, St Louis, Missouri

Hackensack University Medical Center, Hackensack, New Jersey

Levine Children's Hospital, Charlotte, North Carolina

Cleveland Clinic Children's, Cleveland, Ohio

Randall Children's Hospital, Portland, Oregon

Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey, Pennsylvania

Hasbro Children's Hospital, Providence, Rhode Island

Medical University of South Carolina, Charleston, South Carolina

Dell Children's Blood and Cancer Center, Austin, Texas

Children's Medical Center Dallas, Dallas, Texas

Children's Hospital of The King's Daughters, Norfolk, Virginia

Medical College of Wisconsin, Milwaukee, Wisconsin

Canada

Alberta Children's Hospital, Calgary, Alberta

CancerCare Manitoba, Winnipeg, Manitoba

UHC Sainte-Justine, Montreal, Quebec

Montreal Children's Hospital, Montreal, Quebec

CHUQ, Québec, Quebec

CIUSSS de l'Estrie-CHUS, Sherbrooke, Quebec